Board of Management & Directors

Karinza Phoenix

MBA AICD

Executive Chair & Founding CEO

Milton Grannatt

PhD

Founding Non – Executive Director

Tsutomu (Tom) Abe

Non–Executive Director

LLB

Trevor Lockett

Non–Executive Director

PhD

Myopharm

Myopharm Limited
Levels 1, 2 & 3 60 Martin Place
Sydney New South Wales 2000

Our Company

Overview

Investor Welcome

News & Media

Shop

Subscribe to our email alerts

Karinza Phoenix MBA AICD

Executive Chair & Founding CEO

Ms Phoenix has more than 24 years of executive and commercial experience in pharmaceutical, veterinary and capital markets sectors, inclusive of holding operational and marketing roles at Pfizer, Novartis and Zoetis.

Ms Phoenix has a successful track record of product development, registration and marketing launches, incorporating successful commercialisation of numerous market leading blockbuster medicines.

Ms Phoenix has served on the Myopharm Board of Directors for 4 years and has invested in almost all capital raises to date, while focussing on expanding Myopharm’s clinical and commercial initiatives.

Milton Grannatt PhD

Founding Non – Executive Director

Mr Grannatt has more than 35 years’ of broad experience in global pharmaceuticals.

Previously Vice President of Finance, Sterling Winthrop and Vice President of Global Business Development and Licensing at Novartis, Mr Grannatt was additionally a Non-Executive Director at SymBio Pharmaceuticals Limited.

Mr Grannatt is currently a valued Advisor to Myopharm and a number of biotechnology start-ups.

Tsutomu (Tom) Abe LLB

Non–Executive Director

Mr Abe has over 30 years extensive international experience as both General Counsel to Japanese global corporations and as an executive in the global pharmaceuticals industry in business development, licensing and alliance management.

Previously Mr Abe was General Counsel at Fast Retailing Co., Ltd and Kokuyo Co., Ltd and Corporate officer in charge of Global Business Development and Global Alliance Management at SymBio Pharmaceuticals Limited.

Currently Mr Abe is COO at TAK-Circulator Corporation, CLO at nonpi Inc and CEO at Askleon Co. Ltd. Mr Abe holds a Bachelor of Law from Keio University.

Dr Trevor Lockett PhD

Non–Executive Director

A molecular biologist by training, Trevor had a distinguished scientific career with CSIRO, in the latter years leading the Personalised Health Group within CSIRO’s Health & Biosecurity Business Unit. Here he directed research supporting the development of new diagnostic tests for the early detection of colorectal cancer and diet and lifestyle approaches to promoting gastrointestinal health.

In 2017 he joined Rhythm Biosciences as the company’s founding Managing Director, contributing to the successful ASX listing of the company in December 2017. He served as a member of Rhythm’s Board from its inception in 2017, first as an executive director, then as a non-executive Director, retiring from the Board in November of 2024. He was part time Technical Director at Rhythm from July 2020 to December 2023 and continues to consult to the company. He also served as a non-executive director on the board of the private company, Juno Healthcare, from January to December of 2023.

Trevor is an inventor on ten patent and patent application families, is an author on over 100 peer reviewed publications in the scientific literature and is a Member of the Australian Institute of Company Directors.

Dr Kurt Sales PhD PGCM

Chief Operating Officer

Dr Sales has over 25 years of global experience spanning research, drug discovery and development, clinical study support, regulated Bioanalysis and business management across academic, biotech and CRO environments.

With a Bachelor of Science in Medicine (Honours) in Pharmacology, MSc in Biochemistry , PhD in Medical Biochemistry and a Post Graduate Certificate in Management and more than 50 peer-reviewed publications in leading international Scientific Journals, his research career redefined the role of inflammatory cyclooxygenase enzymes, prostanoids, their receptors and signal transduction pathways in cancers and inflammatory disorders of the reproductive tract. In his career in regulated Bioanalysis, Dr Sales supported numerous first in class compounds in clinical development and has regularly taken part in key workshops and discussion forums to contribute to global scientific white papers in Bioanalysis.

Prior to joining Myopharm, Dr Sales held Grant-funded leadership roles at the Medical Research Council in the United Kingdom and South Africa, supporting drug discovery research into novel therapeutic pathways for various inflammatory diseases. At Charles River Laboratories in the United Kingdom he supported preclinical safety studies as Head of Immunology and at Agilex Biolabs supported first in human clinical trials for a range of novel therapeutics as Director of Immunoassay and Chief Scientific Officer.

With experience across research and development, preclinical GLP studies and clinical operations, he will be leading and overseeing Myopharm’s operational and clinical development activities across its pipeline and business operations.

Charles Czank PhD MBA

Head of Clinical Development

Dr Czank has over 15 years’ experience in clinical research and pharmaceutical development across biotech, medtech, and CRO environments.

With a PhD in Biochemistry and an MBA in general management, he has led global diabetes and metabolic disease trials from early phase to Phase III, advancing programs through FDA 505(b)(2) and TGA pathways.

Before joining Myopharm, Dr Czank held senior clinical research leadership roles at Southern Star Research, George Clinical, and the Telethon Kids Institute, and at Leatherhead Food Research, he developed nutritional products for glucose control in Type 2 diabetes.

With expertise in clinical operations, regulatory strategy, and translational research, guiding Myopharm’s clinical programs from development through to commercialisation.

Catherine Owczarek PhD

Consultant

Dr Catherine Owczarek is a discovery to clinic development leader with more than 20 years’ experience supporting therapeutic programs as they progress from early discovery toward clinical readiness. She brings deep expertise in translational science and early development strategy, with a focus on building development pathways that are scientifically rigorous, regulator ready and commercially credible.

Across her career in highly regulated biopharma environments, Dr Owczarek has worked at the interface of discovery research, translational science and early development. She held senior scientific leadership roles at CSL, where she supported multiple programs across immunology and respiratory disease, contributing to assets spanning early discovery through GLP toxicology, product development, first in human readiness and Phase 1-2 clinical trials.

Her experience includes scientific leadership of an early phase clinical program, contributions to programs in clinical development and involvement in a successfully registered therapeutic product. She is recognised for strengthening scientific foundations, clarifying development logic and ensuring data packages meet internal governance and regulatory expectations.

Dr Owczarek holds a PhD from the Australian National University and has an extensive publication and intellectual property record supporting therapeutic development.

Steven Jackson BEc CPA

Chief Financial Officer

Mr Jackson has over 15 years of experience in accounting and corporate governance roles across both listed and unlisted companies. He is a member of CPA Australia and has served as CFO for several ASX-listed companies, gaining extensive expertise across a diverse range of industries.

Mr Jackson is a member of CPA Australia who graduated from the University of Western Australia in 2008 with a Bachelor of Economics majoring in International Business Economics and Money and Banking.

ARKAY Therapeutics LLC

Scientific Advisory Board

ARKAY Therapeutics LLC are a group of globally renowned Professors, Scientists, Practising and Academic Endocrinologists and Regulatory Affairs specialists with extensive clinical trial experience in both big pharmaceutical and private companies. ARKAY’s team are based across the United States of America.

Prof David Church BVSc PhD MACVSc FHEA MRCVS

Scientific Advisory Board

Prof Church graduated from The University of Sydney, after graduation he was appointed as a clinical instructor at The University of Sydney and completed his PhD programme in the Faculty of Medicine looking at various aspects of the pathophysiology of diabetes mellitus.

Later appointed as a member of faculty in small animal medicine at The University of Sydney, Prof Church rose to become Hospital Director of The University Veterinary Centre.

In 2001 Prof Church was appointed Chair of Small Animal Studies at the Royal Veterinary College and head of the newly formed Department of Veterinary Clinical Sciences. The department grew to be one of the largest and successful clinical departments in the world with substantial research grant funding. Prof Church maintains an interest in endocrinology and his current research interests include insulin resistance states in diabetes mellitus and the use of ‘big data’ from general practice for managing animal health and welfare.

Prof Church is the author of over 150 scientific articles, numerous book chapters, and he is editor of the highly successful textbook Small Animal Clinical Pharmacology.